ImmuCell Corporation (ICCC)

Several events have impacted ImmuCell Corp.'s stock price over the past six months. Olivier te Boekhorst was appointed President and CEO, succeeding Michael F. Brigham. ImmuCell announced a strategic shift to focus on its First Defense calf-health franchise and paused further investment in manufacturing Re-Tain after receiving an FDA "Incomplete Letter", resulting in a non-cash impairment charge. Q3 2025 product sales were down, but nine-month and twelve-month sales increased. Full-year 2025 product sales increased, and gross margin improved, but the company reported a net loss. The company increased its manufacturing capacity for First Defense. Kathy Turner was appointed to the Board of Directors. The stock price had increased by 2.47% in the past month and 37.68% over the last 12 months.

ImmuCell Corporation's common stock exhibits some demand seasonality based on 27 years of historical data. June has been the strongest month for the stock, while August tends to be the weakest month. Overall, 8 out of 12 months typically show positive average returns. The consistency score for this seasonal pattern is considered "Poor".

ImmuCell Corporation is an animal health biotechnology company focused on developing, manufacturing, and selling products to enhance the health and productivity of dairy and beef cattle. The company operates in the animal health industry with two main segments: Scours and Mastitis. Its major products include the First Defense product line, which provides immediate immunity to newborn calves against pathogens, and the California Mastitis Test, a diagnostic tool for detecting mastitis. ImmuCell was also developing Re-Tain Drug Product, but investment in its manufacturing has been paused. The company sells its products through animal health distributors.

ImmuCell Corporation is headquartered in Portland, Maine, United States. The company develops, manufactures, and sells its products in the United States and internationally. ImmuCell is actively pursuing international expansion by seeking additional regulatory approvals and building distributor partnerships, with efforts to grow sales in North America and exploring opportunities in other international territories such as Pakistan and India.

ImmuCell's brand reputation has been shaped by its focus on providing scientifically-proven products that reduce the need for traditional antibiotics. The strategic decision to pause investment in Re-Tain was framed as a pivot to focus on expanding its First Defense franchise. Improved gross margins and an operational turnaround leading to net profitability in the first nine months of 2025 could be seen as positive. The appointment of a new CEO and a new board member also aims to strengthen the company's strategic direction.

ImmuCell Corp. has a diverse ownership structure, with institutional investors owning approximately 13.47% of the stock, including major shareholders like Vanguard Group Inc. and Renaissance Technologies LLC. Insiders own about 21.29% of the company's stock, with Norman H. Pessin being the largest individual shareholder. The general public holds approximately 64.56% of the shares.